Alison Moore

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
South San Francisco, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Georgia Erbez, as Attorney-in-Fact for Alison Moore
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Alison Moore

Form 4 holding Chief Technical Officer

Allogene Therapeutics, Inc.

Security class
Common Stock
Shares / value
672,731
Estimated value
$2,135,517
Report date
22 Mar 2023
Price
$3.17
Ownership
Direct
Form 4 holding President and CEO, Director

CODEXIS, INC.

Security class
Common Stock
Shares / value
250,506
Estimated value
$327,436
Report date
06 Feb 2026
Price
$1.31
Ownership
Direct
Form 4 holding President and CEO, Director

CODEXIS, INC.

Security class
Stock Option (Right to Buy)
Shares / value
993,000
Estimated value
Report date
23 Feb 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Technical Officer

Allogene Therapeutics, Inc.

Security class
Stock Option (Right to buy)
Shares / value
432,738
Estimated value
Report date
22 Mar 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Alison Moore

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .